pentobarbital will minimize the level or outcome of ethotoin by affecting hepatic enzyme CYP2C9/10 metabolism. Use Warning/Keep track of.
pentobarbital will reduce the extent or impact of alosetron by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Unidentified.
pentobarbital will lower the level or effect of fosaprepitant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
pentobarbital will decrease the level or result of losartan by impacting hepatic enzyme CYP2C9/10 metabolism. Slight/Significance Unknown.
pentobarbital will decrease the level or influence of ripretinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will minimize the extent or impact of fentanyl intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Carefully. Coadministration of fentanyl with CYP3A4 inducers could lead into a minimize in fentanyl plasma concentrations, lack of efficacy or, maybe, enhancement of the withdrawal syndrome inside of a individual that has produced Actual physical dependence to fentanyl.
Monoamine oxidase inhibitors (MAOI) may perhaps inhibit barbiturate metabolism and lengthen barbiturate effects; monitor intently
pentobarbital will reduce the level or outcome of etravirine by affecting hepatic enzyme CYP2C9/10 metabolism. Use Warning/Monitor.
pentobarbital decreases amounts of ponatinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Stay away check here from Until the coadministration outweighs the doable hazard of ponatinib underexposure; keep an eye on for indications of minimized efficacy.
pentobarbital will lessen the extent or impact of dexamethasone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
When the buprenorphine dose is insufficient along with the CYP3A4 inducer cannot be diminished or discontinued, transition the client back again to a buprenorphine formulation that allows dose changes.
pentobarbital will decrease the extent or influence of rabeprazole by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Unknown.
pentobarbital will reduce the level or influence of rolapitant by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Stay away from or Use Alternate Drug. Extensive-term coadministration of robust CYP3A4 inducers with rolapitant might drastically minimize rolapitant efficacy.
pentobarbital will lower the level or result of fostemsavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.